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Ultraconserved region-containing Transformer 2β4 controls
senescence of colon cancer cells
K Kajita, Y Kuwano, Y Satake, S Kano, K Kurokawa, Y Akaike, K Masuda, K Nishida and K Rokutan
Ultraconserved regions (UCRs) are4200 bp genomic segments with perfect human-to-rodent sequence identity. Transcribed UCRs
constitute a new category of noncoding RNAs whose functions remain poorly understood. The human transformer 2β (TRA2B) gene
contains a 419-bp UCR spanning the 276-bp exon 2 and its neighboring introns. TRA2B exon 2 has premature stop codons, whereas
an exon 2-containing splice variant (TRA2β4) was expressed preferentially in the nuclei of human colon cancer cells. TRA2β4
knockdown p53-independently stimulated CDKN1A transcription and increased p21, resulting in the appearance of senescent cells.
Biotin pull-down and RNA immunoprecipitation assays revealed that TRA2β4 interacted with Sp1 through a Sp1-binding sequence
(485-GGGG-488) in a stem-loop structure of exon 2. Mutation of this sequence (485-AAGG-488) disrupted the stem-loop structure,
blocked the interaction with Sp1 and increased CDKN1A transcription. Overexpression of TRA2β4 signiﬁcantly decreased CDKN1A
mRNA levels and accelerated cell growth, but the introduction of the mutation in the Sp1-binding sequence completely canceled
these effects. Taken together, TRA2β4 may sequester Sp1 from occupying promoters of target genes including CDKN1A, promoting
cell growth by interrupting the senescence-related gene expression program. This novel function of TRA2β4 may uncover an
oncogenic function of transcribed UCRs.
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INTRODUCTION
Alternative splicing of pre-mRNAs generates protein diversity
from a limited number of genes.1 The utilization of alternative
splice sites is regulated by cis-acting elements and trans-acting
factors through the interaction of a family of serine/arginine
(SR)-rich splicing factors (SRSFs) and heterogeneous nuclear
ribonucleoproteins. Alternative splicing occurs in a developmental
stage-, sex- or tissue-speciﬁc manner and in response to
the surrounding microenvironment.2,3 High-throughput RNA
sequencing of tissue-speciﬁc splicing events indicates that
490% of human genes produce multiple spliced isoforms.3 At
the same time, aberrant alternative splicing participates in many
genetic and acquired diseases including cancer.2,4
An SR-like protein transformer 2β (Tra2β) regulates splice site
selection of several genes encoding calcitonin/calcitonin
gene-related peptide (CGRP), survival motor neuron 1 (SMN1)
and microtubule-associated protein tau (TAU) in a concentration-
dependent manner.5–7 Several lines of evidence suggest that
overexpressed Tra2β may be involved in the pathogenesis of
cancer.8–10 The human TRA2β (TRA2B) gene is composed of 10
exons and 9 introns. TRA2B contains a 419-bp genomic segment
with perfect human-to-rodent sequence identity, termed the
ultraconserved region (UCR; uc.138, see Supplementary Figure S1)
spanning the 276-bp exon 2 and its neighboring introns.11,12
TRA2B generates ﬁve mRNA isoforms (TRA2β1–5) through
alternative splicing and usage of alternative promoters or
polyadenylation sites (Figure 1a).12 Because of the existence of
multiple premature termination codons (PTCs) in TRA2B exon 2, an
exon 2-containing TRA2β4 mRNA isoform (hereafter referred as
TRA2β4) is not translated and should be actively degraded
through nonsense-mediated mRNA decay (NMD), a surveillance
mechanism that degrades PTC-containing mRNAs. However,
oxidative stress speciﬁcally facilitated TRA2β4 isoform production
in rat gastric mucosa and a human gastric cancer cell line (AGS).13
Recently, it has become apparent that non-protein-coding
RNAs (ncRNAs) are functionally important for normal development
and physiology, as well as for pathologic processes.14 ncRNAs can
be broadly classiﬁed into small (18–200 nt) and long ncRNAs
(200 nt to 4100 kb).15 Among them, epigenetic and genetic
defects in a class of small ncRNAs called microRNAs are now
recognized as a common hallmark of cancer. However, other
ncRNAs, such as transcribed UCRs (T-UCRs), small nucleolar RNAs,
PIWI-interacting RNAs or large intergenic noncoding RNAs, may
also contribute to the development of many different diseases.
There are 481 described UCRs, and more than half of them do not
encode any protein.11 However, 68% of UCRs are transcribed,
constituting a new category of ncRNAs, the T-UCRs.16 The wide
distribution in the genome and lack of natural variation in the
human population suggest an essential functional role in normal
cells.11,17 Recent genome-wide expression proﬁling studies have
shown that certain T-UCRs are differentially expressed in human
leukemias and carcinomas.16,18,19 Expression of those UCRs was
suggested to be regulated by microRNAs, and the inhibition of an
overexpressed T-UCR (uc. 73) induced apoptosis of colon cancer
cells.16 T-UCRs are widely expressed in neuroblastomas and their
expression correlates with important clinicogenetic parameters
such as MYCN ampliﬁcation status.20 However, the functional role
of T-UCRs in cancer development is largely unknown.
Here, we introduce TRA2β4 as a functional T-UCR preferentially
expressed in colon cancer cells. TRA2β4 may exert an oncogenic
function by controlling senescence of colon cancer cells.
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RESULTS
Colon cancer cells upregulate TRA2β4 mRNA isoform expression
PTC-containing TRA2β4 mRNA isoform (TRA2β4) was considered to
be degraded through NMD. However, when expression levels of
TRA2β4 and TRA2β1 were examined in different colon cancer cell
lines, all cell lines tested expressed signiﬁcant amounts of TRA2β4
(Figure 1b, upper panel). TRA2β4 levels were estimated to be
10–20% of those of TRA2β1mRNA that encodes a full-length Tra2β
protein. On the other hand, TRA2β1 mRNA was not consistently
overexpressed in the colon cancer cell lines (Figure 1b, lower
panel). Human colon cancer (HCT116) cells expressed mainly
TRA2β1 mRNA and increased TRA2β4 isoform production after
exposure to sodium arsenite (Supplementary Figures S2b and c) as
similarly observed in gastric cancer cells.13
Inactivation of NMD with cycloheximide increased the amounts
of PTC-containing mRNA variants of SRSF3 and SRSF9 (Figure 1c).
In contrast, cycloheximide treatment failed to increase TRA2β4
levels, which was conﬁrmed by quantitative real-time reverse
transcription– (qPCR) (Figure 1c) and Northern blot analysis
(Figure 1d). Two different small interfering RNAs (siRNAs) targeting
a key regulator of NMD (UPF1) effectively reduced UPF1 mRNA
levels (Supplementary Figure S3a) and signiﬁcantly increased the
amounts of SRSF3 and SRSF9 PTC variants (Supplementary
Figure S3b), but they did not increase TRA2β4 (Figure 1e).
To explain why NMD did not control TRA2β4 expression, we
prepared nuclear and cytoplasmic fractions from HCT116 cells. The
purity of each fraction was conﬁrmed by western blotting using
antibodies for cytosolic (α-tubulin) and nuclear (heterogeneous
nuclear ribonucleoprotein C1/C2) marker proteins (Figure 2a), and
Figure 1. Expression of TRA2β1 and TRA2β4 in colon cancer cell lines. (a) Schematic diagram of the human TRA2B gene. Exons (ex) are indicated
by open boxes and Arabic numbers. Filled boxes denote the ultraconserved exon 2. Five splice variants generated from TRA2B and the use of
each exon are shown. (b) Amounts of TRA2β4 (upper panel) and TRA2β1 (lower panel) mRNAs in normal human colon and colon cancer cell
lines (HCT116, RKO, HT29, Caco-2, T84 and SW480) were measured by qPCR using GAPDH mRNA as an endogenous quantity control. Values
are means± s.d. from three independent experiments. *Signiﬁcantly different by analysis of variance (ANOVA) and Bonferroni test (Po0.05).
(c) HCT116 cells were treated with 10 μg/ml cycloheximide (CHX) for 4 h to inhibit NMD. Then, changes in mRNA levels of TRA2β1, TRA2β4,
SRSF3 PTC and SRSF9 PTC were measured by qPCR using GAPDH mRNA as an endogenous quantity control. Values are means± s.d. from three
independent experiments. (d) After treatment of HCT116 cells with 50 or 100 μg/ml CHX for 4 h, TRA2β4 levels were assayed by Northern
hybridization with a locked nucleic acid (LNA) probe targeting for exon 2. 18S rRNA was used as a loading control. (e) After treatment of
HCT116 cells with 10 nM of two different UPF1 siRNAs for 48 h, changes in TRA2β4 mRNA levels were measured by qPCR using GAPDHmRNA as
an endogenous quantity control. Values are means± s.d. from three independent experiments.
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by reverse transcription–PCR (RT–PCR) using primers targeting
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) pre-mRNA
(Figure 2b). RT–PCR ampliﬁed TRA2β4 in nuclear fractions
containing GAPDH pre-mRNA, but not in cytosolic fractions,
whereas TRA2β1 mRNA was distributed in both nuclear and
cytoplasmic fractions (Figure 2b). qPCR measurement showed that
TRA2β4 was signiﬁcantly enriched in the nucleus, compared with
TRA2β1 and GAPDH mRNAs (Figure 2c). RNA ﬂuorescence in situ
hybridization revealed that overexpressed TRA2β4 signals were
present preferentially in the nuclei, whereas TRA2β1 mRNA
signals were distributed in both the nucleus and the cytoplasm
(Figure 2d). We also conﬁrmed that HeLa cells constitutively
expressed TRA2β4 in their nuclei similar to a nucleus-retained
noncoding RNA (MEN ε/β) (Supplementary Figure S4a). Transiently
overexpressed TRA2β4 was retained predominantly in the nuclei
of HEK293T as well as of HeLa cells (Supplementary Figure S4b).
These results suggest that signiﬁcant amounts of TRA2β4 are
retained in the nucleus and may escape from NMD-mediated
degradation.
TRA2β4 knockdown inhibits cell growth
To test the possibility that the TRA2β4 variant might be a
functional T-UCR, we prepared two different siRNAs against TRA2β
mRNAs (Tra2β siRNA targeting exon 6 and TRA2β4 siRNA targeting
exon 2) and examined the effects of these siRNAs on cell growth.
Although Tra2β siRNA was designed to degrade both TRA2β1 and
TRA2β4 isoforms, it degraded TRA2β1 more effectively than
TRA2β4 probably because of the predominant expression of the
TRA2β1 isoform (Figure 3a). Consequently, Tra2β siRNA effectively
reduced Tra2β protein (Figure 3b). In contrast, TRA2β4 siRNA
selectively reduced TRA2β4 without changing TRA2β1 mRNA and
Tra2β protein levels (Figures 3a and b). Treatment with Tra2β
siRNA signiﬁcantly inhibited cell growth (Figure 3c) in association
with an increase in terminal deoxynucleotidyl transferase-
mediated UTP end labeling (TUNEL)-positive cells (Figure 3d)
and activation of poly(ADP-ribose) polymerase (PARP) and
caspase-3 (Figure 3e). It was of interest that TRA2β4 siRNA did
not change TRA2β1 mRNA or Tra2β protein levels, but it did inhibit
cell growth (Figure 3c). Moreover, the selective TRA2β4
knockdown did not signiﬁcantly increase TUNEL-positive cells
(Figure 3d) and did not activate PARP and caspase-3 (Figure 3e).
TRA2β4 knockdown induces cellular senescence
As shown in Figure 4a, TRA2β4 siRNA-treated HCT116 cells
displayed unique morphological changes, that is, the cells spread
out their cytoplasm and became thinner. These enlarged cells
were positive for senescence-associated β-galactosidase (SA-β-gal)
(Figure 4a). To conﬁrm that TRA2β4 siRNA induced cellular
senescence, we examined the expression of cyclin-dependent
kinase inhibitors that have a crucial role in cell-cycle arrest and
induction of senescence.21 Owing to a frameshift mutation in the
INK4A gene and the hypermethylated promoter, p16 protein was
undetectable in HCT116 cells.22 As shown in Figure 4b, treatment
with TRA2β4 siRNA, but not with Tra2β1 siRNA, increased p21
levels. To avoid off-targeting effects, an additional siRNA targeting
another sequence in TRA2β4 (TRA2β4 siRNA no. 2) were used.
Figure 2. Subcellular distribution of TRA2β4 in HCT116 cells. (a) After nuclear and cytosolic fractions were prepared from HCT116 cells, the
purity of each fraction was monitored by measuring a cytosolic protein (α-tubulin) and a nuclear protein (heterogeneous nuclear
ribonucleoprotein (hnRNP) C1/C2) by western blotting. (b) Total RNA was extracted from each fraction and TRA2β1 mRNA or TRA2β4 was
ampliﬁed by RT–PCR using speciﬁc primer sets. The purity of each faction was also assessed by RT–PCR measurement of GAPDH pre-mRNA.
(c) TRA2β1, TRA2β4 and GAPDH mRNA levels in each fraction were measured by qPCR. Nuclear-to-cytosolic distribution ratio of each mRNA was
calculated. Nuclear enrichment of TRA2β1 mRNA or TRA2β4 is indicated by comparing values to nuclear/cytosolic distribution ratio of GAPDH
mRNA. Values are means± s.d. from three independent experiments. (d) Subcellular localization of TRA2β4 and TRA2β1 mRNA in HCT116 cells
was examined by RNA ﬂuorescence in situ hybridization (RNA-FISH) using locked nucleic acid (LNA) probes against exon 2 and exon 1–3
junction of TRA2β1 mRNA (green), respectively, as described in Materials and methods section. Cells were counterstained with TO-PRO-3
(blue). Scale bars, 5 μm.
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Transfection of TRA2β4 siRNA no. 2 also increased CDKN1A mRNA
and p21 protein levels, and the percentage of SA-β-gal-positive
cells (Supplementary Figure S5). It should be noted that
TRA2β4 knockdown did not induce p53 (Figure 4b), and that
TRA2β4 siRNA-mediated p21 induction occurred even in p53-null
(p53− /−) HCT116 cells (Figure 4c). These results suggested that
the reduction of TRA2β4 might increase CDKN1A mRNA and
p21 protein levels in a p53-independent manner. We also
conﬁrmed that TRA2β4 knockdown similarly induced
morphological changes and SA-β-gal in p53− /− HCT116 cells
(Supplementary Figures S6a and b).
A human ﬁbroblast cell line (TIG-3) exhibited an age-associated
reduction of TRA2β4 levels (Figure 4d). Reciprocal changes in
TRA2β4 and CDKN1A mRNA expression were also observed along
with senescence of TIG-3 and another human ﬁbroblast cell line
(WI-38); senescent cells decreased TRA2β4 expression in
association with increased expression of CDKN1A mRNA
(Figures 4e and f). These results suggest that TRA2β4 may regulate
p21 expression during replicative senescence.
TRA2β4 interacts with Sp1 and regulates CDKN1A transcription
TRA2β4 knockdown did not affect the stability of CDKN1A mRNA
(Supplementary Figure S7a) and p21 protein (Supplementary
Figure S7b) or the translation rate of p21 (Supplementary
Figure S7c), suggesting that the reduction of TRA2β4 may facilitate
CDKN1A transcription. To conﬁrm this, we cloned the 5′ ﬂank of
CDKN1A (from − 2688 to +31 bp), and HCT116 cells were
transfected with a luciferase reporter construct containing
− 2688/+31, − 774/+31 or − 163/+31 bp region of the human
CDKN1A promoter (Figure 5a). The − 2688/+31 bp region
contained two p53-binding sites and exhibited basal and
TRA2β4 siRNA-mediated upregulation of CDKN1A promoter
activity (Figure 5a). The − 163/+31 bp region as well as the
− 774/+31 bp region lost the p53-binding sites and markedly
reduced the basal promoter activity. However, these two regions
still responded to TRA2β4 knockdown and increased the luciferase
activity. The − 163/+31 bp region contained a cluster of
Sp1-binding sites that likely mediated the response to TRA2β4
knockdown. To further investigate how reduction of TRA2β4
resulted in the stimulation of CDKN1A transcription, we performed
chromatin immunoprecipitation assays with an anti-Sp1 antibody
using control or TRA2β4 siRNA-treated HCT116. Sp1 did not bind
to the -560/-226 region or the − 325/+51 bp region in control
siRNA-treated cells (Figure 5b), whereas in TRA2β4 siRNA-treated
cells, Sp1 bound to the -325/+51 bp region containing the cluster
of Sp1-binding sites, but not to the − 560/− 226 bp region
(Figure 5b). These results suggest that Sp1 binding to the CDKN1A
Figure 3. Effect of TRA2β4 silencing on cell proliferation and apoptosis. (a) After HCT116 cells were treated with 10 nM of TRA2β4 or Tra2β siRNA
for 48 h, TRA2β1 mRNA and TRA2β4 levels were measured by qPCR using GAPDH as an endogenous quantity control. Values are means± s.d.
from six independent experiments. (b) HCT116 cells were treated with 10 nM TRA2β4, Tra2β or control siRNA for 48 h, and then the amounts of
Tra2β were measured by western blotting using β-actin as a loading control. (c) HCT116 cells (1.5 × 104 cells) were seeded in 35-mm-diameter
dishes and transfected with 10 nM TRA2β4, Tra2β or control siRNA. Subsequently, growing cells were harvested and counted at the indicated
times. Values are means± s.d. from four independent experiments. *Signiﬁcantly different by analysis of variance (ANOVA) and Bonferroni test
(Po0.05). (d) After HCT116 cells were treated with 10 nM TRA2β4, Tra2β or control siRNA for 24 h, they were labeled using the DeadEnd
Colorimetric TUNEL system (left panels), and the percentages of TUNEL-positive cells were determined (right panel). Values are means± s.d.
from three independent experiments. *Signiﬁcantly different by ANOVA and Bonferroni test (Po0.05). Scale bars, 50 μm. (e) After treatment of
HCT116 cells with 10 nM TRA2β4, Tra2β or control siRNA for 48 h, whole-cell lysates were prepared from these cells. The levels of unprocessed
or cleaved caspase-3 and PARP were measured by western blotting using β-actin as a loading control.
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promoter may be blocked when signiﬁcant amounts of
TRA2β4 are present in the nucleus of HCT116 cells. The
crucial role of Sp1 was also conﬁrmed by two additional
ﬁndings. That is, knockdown of Sp1 almost signiﬁcantly blocked
the TRA2β4 silencing-induced upregulation of CDKN1A
promoter activity (Figure 5c), CDKNA1A mRNA expression
(Figure 5d), and p21 protein expression (Figure 5e). In addition,
co-transfection of Sp1 siRNA with TRA2β4 siRNA reduced
TRA2β4-mediated increase in the percentage of SA-β-gal-positive
cells (Figure 5d). Thus, the Sp1 elements seemed to play a pivotal
role in the transcriptional activation of CDKN1A after silencing of
TRA2β4.
As shown in Figure 6a, RNA immunoprecipitation (RIP) assays
indicated that an anti-Sp1 antibody retrieved endogenous TRA2β4
more effectively than TRA2β1mRNA or other control RNAs, such as
UBC, U6 and 18S, suggesting the association between Sp1 and
TRA2β4. We prepared a plasmid encoding full-length TRA2β4
bearing bacteriophage MS2 hairpins (pMS-TRA2β4; Figure 6b).
HCT116 cells were co-transfected with pMS-TRA2β4 and
pMS2-yellow ﬂuorescence protein (YFP) bearing an YFP-fused
MS2-binding protein.23 Using this system, we again conﬁrmed
the association between MS2-tagged TRA2β4 and Sp1 in
YFP-immunoprecipitated materials (Figure 6c). The presence of
exon 2 in TRA2β4 is the only difference between TRA2β4 and
TRA2β1, biotin-pull-down assays with HCT116 cells transcribing
TRA2β exon 1, 2 or 3 RNA demonstrated the speciﬁc association of
Sp1 with TRA2β exon 2 RNA (Figure 6d). As shown in Figure 6e,
TRA2β4 exon 2 contains two Sp1 consensus sequences
(485-GGGG-488 and 515-ACGG-518). CentroidFold (http://www.
ncrna.org/centroidfold) and M-FOLD (http://mfold.rna.albany.edu/
?q =mfold) programs indicate that TRA2β4 contains a stem-loop
structure within exon 2 (449–488 nt, underlined in Figure 6e).
Both programs also indicate that the introduction of two-point
mutations at the Sp1-binding sequence (exon 2 mt-1,
485-GGGG-488 to 485-AAGG-488) completely disrupts the
stem-loop structure (Figure 6e). The MS2 RNA hairpin-tagging
system was again used to identify the interaction between exon 2
and Sp1. We constructed pMS2-LUC (Renilla luciferase gene
(LUC))-exon 2 wild-type (exon 2 wt), pMS2-LUC-exon 2 mt-1 and
pMS2-LUC-exon 2 mutated at another Sp1-binding sequence
(exon 2 mt-2, 515-ACGG-518 to 515-ACAA-518) (Figure 6f) and
transfected into HCT116 cells (Figure 6g). RIP between Sp1 and
LUC-fused exon 2 constructs indicated that two-point mutations in
the stem-loop motif (exon 2 mt-1), but not in another Sp1-binding
Figure 4. TRA2β4 knockdown induces cellular senescence. (a) HCT116 cells were transfected with 10 nM Tra2β, TRA2β4 or control siRNA for
72 h. They were then subjected to SA-β-gal staining. Scale bars, 10 μm. (b) After the transfection for 48 h, amounts of p21and p53 were
measured by western blotting with respective antibodies (left panel). P21 levels were quantiﬁed using the Image J software (NIH, Bethesda,
MD, USA) (right panel). β-Actin was used as a loading control. (c) After wild-type (p53+/+) or p53− /− HCT116 cells were treated with 10 nM
TRA2β4 or control siRNAs for 48 h, CDKN1A mRNA levels were determined by qPCR using GAPDH mRNA as an endogenous quantity control.
Data are expressed as fold changes compared with those in control siRNA-treated cells. Values are means± s.d. (n= 5). (d) TRA2β4 levels in TIG
cells at population doubling levels (PDL) 37, 40, 43, 53 and 62 were measured by qPCR using GAPDH mRNA as an endogenous quantity
control. Data were expressed as fold changes relative to the levels in PDL 37 TIG-3 cells. Values are means± s.d. (n= 3). (e and f) TRA2β4 and
CDKN1A mRNA levels in young (PDL 37) and senescent (PDL 62) TIG-3 cells as well as young (PDL 29) and senescent (PDL 55) WI-38 cells were
measured by qPCR using GAPDH mRNA as an endogenous quantity control. Values are means± s.d. from three independent experiments.
*Signiﬁcantly different by analysis of variance (ANOVA) and Bonferroni test (Po0.05) compared with those in control siRNA-treated cells.
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Figure 5. TRA2β4 modiﬁes promoter activity of the CDKN1A gene. (a) Twenty-four hours after transfection with 10 nM TRA2β4 or control siRNA,
HCT116 cells were transiently transfected with luciferase reporter plasmids driven by − 2688/+31, − 774/+31 or − 163/+31 bp promoter
fragments of CDKN1A for 24 h. Luciferase activities in these cells were measured using the Dual-Luciferase Reporter Assay System.
*Signiﬁcantly decreased compared with control siRNA-treated cells (Po0.05 by analysis of variance (ANOVA) and Bonferroni test). (b) After
treatment with TRA2β4 or control siRNA for 48 h, HCT116 cells were subjected to chromatin immunoprecipitation (ChIP) assays.
Formaldehyde-crosslinked nuclear extracts were immunoprecipitated with an anti-Sp1 antibody or normal rabbit IgG (IgG). PCR was
performed using an input nuclear chromatin fraction as a template (input). Speciﬁc PCR products corresponding to the region of the CDKN1A
promoter containing the Sp1-binding sites were ampliﬁed and separated by agarose gel electrophoresis followed by ethidium bromide
staining. (c) After treatment with 10 nM Sp1, TRA2β4 or control siRNA for 24 h, HCT116 cells were transiently transfected with the luciferase
plasmid (pGL3-CDKN1A − 163/+31) for 24 h. Luciferase activities in these cells were measured using the Dual-Luciferase Reporter Assay System.
Values are means± s.d. (n= 4). *Signiﬁcantly different (Po0.05 by ANOVA and Bonferroni test). (d and e) After HCT116 cells were treated with
TRA2β4 and/or Sp1 siRNA nos 1/2 as indicated for 24 h, expression levels of CDKN1A mRNA and p21 were analyzed by qPCR and western
blotting. (f) After silencing of TRA2β4 and/or Sp1 nos 1/2, the cells were stained with SA-β-gal and then one hundred cells per individual
sample in three independent ﬁelds were measured. *Signiﬁcantly different (Po0.05 by ANOVA and Bonferroni test).
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site (exon 2 mt-2), signiﬁcantly blocked the association between
TRA2β4 exon 2 and Sp1 (Figure 6h), suggesting a crucial role
of the consensus Sp1-binding site (485-GGGG-488) within the
stem-loop motif.
We also examined whether the interaction between TRA2β4 and
Sp1 was actually involved in regulating the expression of other
Sp1-regulated genes, and found that TRA2β4 knockdown
signiﬁcantly increased the expression of KLF5, DRG2 and PRKRA
Figure 6. TRA2β4 binds to Sp1 via exon 2. (a) Nuclear lysates prepared from UV-crosslinked HCT116 cells were subjected to an RIP assay using
an anti-Sp1 antibody or normal mouse IgG. Immunoprecipitated RNAs were quantiﬁed by qPCR. Data are shown as enrichment relative to
values obtained with normal mouse IgG. Values are means± s.d. (n= 4). (b) Scheme for full-length TRA2β4 bearing bacteriophage MS2 hairpins
(pMS-TRA2β4). YFP, yellow ﬂuorescence protein. (c) After HCT116 cells were co-transfected with pMS2-YFP and pMS-TRA2β4 or control mock
(pMS), association between Sp1 and TRA2β4 was analyzed using immunoprecipitaion with anti-YFP antibody and western blotting with anti-
Sp1 antibody. (d) Nuclear fractions (40 μg) prepared from HCT116 cells were incubated with 1 μg of biotinylated transcripts designed as exon
1 (ex1), exon 2 (ex2) and exon 3 (ex3) of TRA2β4 in 10 mM Tris-HCl buffer, pH 8.0, containing 1 mM EDTA, 250 mM NaCl and 0.5% Triton X-100 for
1 h at room temperature. RNA–protein complexes were isolated with paramagnetic streptavidin-conjugated Dynabeads, and bound Sp1 was
detected by western blotting. (e) Nucleotide sequence of TRA2β4 exon 2. Two consensus Sp1-binding sites are boxed. Formation of stem-loop
structure of TRA2β4 exon 2 RNA (449–488 nt) and its disruption by the mutation of 485-GGGG-488 to 485-AAGG-488 are shown below. These
structures were predicted using CentroidFold and M-FOLD programs. (f) Scheme for pMS2-LUC (Renilla luciferase gene (LUC)), pMS2-LUC-exon
2 wild-type (pMS-ex2 wt), pMS2-LUC-exon 2 mt-1 (pMS-ex2mt-1), and pMS2-LUC-exon 2 mt-2 (pMS-ex2mt-2). Arrows indicate a primer set
used. (g and h) Nuclear lysates prepared from UV-crosslinked HCT116 cells were subjected to an RIP assay using an anti-Sp1 antibody.
Immunoprecipitated LUC-fused exon 2 RNAs were measured by qPCR. Data are shown as enrichment relative to values obtained from amount
of each input. Values are means± s.d. (n= 4).
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mRNAs (Supplementary Figure S8). Sp1 is crucial for transcription
of these genes.24–26
Expression of TRA2β4 in colon cancer cells promotes cell growth
To investigate the possible roles of TRA2β4 in human colon cancer,
we generated a pCMV construct encoding TRA2β4 (pCMV-TRA2β4)
or TRA2β4 containing the mutation (exon 2 mt-1, 485-GGGG-488
to 485-AAGG-488) in the stem-loop motif (pCMV-TRA2β4mt).
Overexpression of TRA2β4 could signiﬁcantly decease CDKN1A
mRNA levels and accelerate cell growth, but the introduction of
the mutation completely cancel these effects (Figures 7a and b).
We also conﬁrmed that the increased levels of TRA2β4 or
TRA2β4mt did not affect TRA2β1 and p53 mRNA levels (Figure 7a).
Finally, we measured the expression of TRA2β4 in 24 different
cDNA libraries prepared from patients with colon cancer
(Figure 7c). The relative expression of TRA2β4 varied depending
on individual paired samples; however, colon cancer tissues
expressed signiﬁcantly higher levels of TRA2β4, compared with
surrounding normal tissues.
DISCUSSION
Among 481 UCRs discovered, 325 UCRs are transcribed and
implicated to function as noncoding RNAs, whereas their speciﬁc
functions are not fully investigated.16 We show here that human
colon cancer cells express signiﬁcant amounts of a T-UCR
(TRA2β4), which is transcribed from uc 281. It has been shown
that aberrant expression of speciﬁc T-UCRs is associated with
chronic lymphocytic leukemia, colorectal cancer and hepatocel-
lular carcinoma.16,18,19 We previously reported that Hu antigen R
regulated alternative splicing of TRA2β to selectively produce
TRA2β4 in human colon cancer cells under oxidative stress.27
Although TRA2β4 is a PTC variant, transcribed TRA2β4 was retained
preferentially within the nucleus and resistant to the RNA
surveillance NMD. Distinct ncRNAs retained within the mammalian
cell nucleus are now referred to as nuclear-retained regulatory
RNAs, and they are suggested to have structural roles or act as
riboregulators.15,28,29 We suggest here that TRA2β4 may function
as a novel regulator of senescence in colon cancer cells.
Tra2β is overexpressed in several types of cancers and has been
suggested to participate in their abnormal growth.2,8 In fact, our
previous studies showed that Tra2β knockdown inhibited
proliferation of colon cancer cells and induced their apoptotic cell
death.9,10 In the present study, we found that TRA2β4 (rather than
Tra2β-encoding TRA2β1) was consistently overexpressed in all
colon cancer cell lines tested. Although selective reduction of
TRA2β4 inhibited cell growth, it did not stimulate apoptosis, but
facilitated cellular senescence. These results suggest novel
functions of TRA2β4 distinct from those of Tra2β protein. Cellular
senescence is regulated by multiple factors, including p53, pRb
and cyclin-dependent kinase inhibitors (p21, p16INK4a, p14ARF and
p15INK4b). p16INK4a is one of the crucial factors for senescence in
human tumors.30 However, like many other cancer cell lines, the
p16INK4A gene is silenced in HCT116 cells owing to a frameshift
mutation and the hypermethylated promoter.22 In contrast,
TRA2β4 knockdown, but not Tra2β knockdown, induced p21
without changing p53 expression. The induction of p21 was
observed even in p53− /− HCT116 cells. Upregulation of p21
induces senescence and the inactivation of this protein prevents
senescence of colon cancer cells.31,32 Thus, p21 was likely to be
one of the key factors in the TRA2β4 knockdown-induced growth
arrest and senescence of HCT116. Replicative senescence-
dependent decline of TRA2β4 levels and a reciprocal induction
of p21 observed in human ﬁbroblast cell lines also support an
important role of TRA2β4 in the regulation of cellular senescence.
TRA2β4 knockdown could increase p21 levels in a p53-
independent manner and it did not change either the stability
Figure 7. Expression of TRA2β4 in colon cancers. (a) HCT116 cells were transfected with pcDNA3.1 (mock), pCMV-TRA2β4 or pCMV-TRA2β4
mutated in the stem-loop motif (pCMV-TRA2β4mt, 485-AAGG-488) for 48 h. mRNA levels were measured by qPCR using GAPDH as an
endogenous quantity control. *Signiﬁcantly decreased compared with mock-treated cells (Po0.05 by Student’s t-test). (b) After transfection of
HCT116 cells (1 × 104 cells per 24-well dish) with pcDNA3.1 (mock), pCMV-TRA2β4 or pCMV-TRA2β4mt, the number of growing cells were
measured using CellTiter96 AQueous Cell Proliferation Assay (MTS). Values expressed as means± s.d. (n= 3). *Signiﬁcantly increased compared
with mock-transfected cells (Po0.05 by Student's t-test). (c) Using human colon cancer tissue qPCR arrays (TissueScan, HCRT103), TRA2β4
expressed in cDNAs from adenocarcinomas of the colon and surrounding normal colon tissues were measured by qPCR in 24 patients. Values
were normalized to ACTB mRNA levels.
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or translation rate of CDKN1A mRNA. Based on the results, we
speculated that TRA2β4might directly regulate transcription of the
CDKN1A gene, and found that TRA2β4 interacted with Sp1 via
exon 2 and regulated CDKN1A mRNA expression. These results
suggest that aberrantly expressed TRA2β4 may prevent Sp1 from
occupying promoters of target genes, including CDKN1A, and thus
promote cell survival by interrupting the senescence-related gene
expression program. Sp1 is crucial for basal transcription of KLF5,
DRG2 and PRKRA.24–26 We conﬁrmed that TRA2β4 knockdown
signiﬁcantly increased the expression of these mRNAs in HCT116
cells, suggesting that interactions between TRA2β4 and Sp1 may
be able to signiﬁcantly alter the gene expression program.
Although the precise mechanism underlying the function of
ncRNAs remains poorly understood, one emerging theme is the
interaction between ncRNAs and protein complexes.33,34 Several
ncRNAs are required for the precise localization of chromatin
proteins on genomic DNA targets.35 ncRNAs can also regulate the
activity of protein complexes. An ncRNA upstream of CCND1
(ncRNACCND1) and the NRON ncRNA can bind to RNA-binding
proteins or transcription factors and change their activities.36,37
Distinct ncRNAs can work as molecular ‘decoys’. For example, the
GAS5 ncRNA binds to the glucocorticoid receptor, blocking the
correct binding to its regulatory elements.38 The long ncRNA
PANDA interacts with the transcription factor NF-YA and limits the
expression of proapoptotic genes, leading to apoptosis.39
At present, however, any T-UCR–protein interaction has not been
documented.
TRA2β exon 2 has four purine-rich exonic splicing enhancers.
Exonic splicing enhancer possesses an activity to retain RNAs in
the nucleus through a saturable nuclear retention factor.40
Four purine-rich exonic splicing enhancers in TRA2β exon 2 may
be important for nuclear retention of TRA2β4 to interact with Sp1
and other regulatory factors. In addition, RNA secondary
structures, especially construction of stems, affected the
RNA-protein-binding activity.41 Ultraconserved cDNA segments
with AT-rich elements are resistant to secondary structure
formation, keeping the segments open to allow regulatory factor
binding.42 This would explain why Sp1 could bind preferentially to
AT-rich exon 2 of TRA2β4. TRA2β4 exon 2 contains predictive
Sp1-binding sites (485-GGGG-488 and 515-ACGG-518).
CentroidFold and M-FOLD programs indicate the presence of a
stem-loop structure (449–488 nt) within exon 2, which includes
one Sp1-binding site (485-GGGG-488). Mutations of this site
(485-AAGG-488) disrupted the stem-loop structure and eliminated
the association between Sp1 and TRA2β4 exon 2. Thus, the
consensus Sp1-binding site seems to be crucial for the interaction
of TRA2β4 exon 2 with Sp1.
Overexpression of full-length TRA2β4 in HCT116 cells
signiﬁcantly reduced CDKN1A mRNA expression and accelerated
their proliferation. The mutations (485-AAGG-488) completely
eliminated these effects, again suggesting a crucial role of the
consensus Sp1-binding site in the TRA2β4-mediated control of cell
fate. Finally, we conﬁrmed that colon cancer tissues expressed
signiﬁcantly higher amounts of TRA2β4.
The present study suggests that the TRA2B gene may control
both apoptosis and senescence of colon cancer cells by
generating different splice isoforms (TRA2β1 and TRA2β4).
TRA2β4 RNA is likely to be a new anti-senescence factor working
speciﬁcally in cancer cells. Cellular senescence is one of the
important tumor-suppressive barriers.30–32,43 It inhibits tumor cell
proliferation and suppresses tumor cell motility, indicating that
the induction of senescence results in the suppression of tumor
cell growth, invasion and metastasis. Moreover, TRA2β4
knockdown could facilitate cellular senescence even in
p53-deﬁcient cells. Thus, TRA2β4 might be a novel tumorigenic
ncRNA and a potential therapeutic target for colon cancer.
MATERIALS AND METHODS
Cell growth, apoptosis and senescence assays
Wild-type and p53− /− HCT 116 cells were cultured in McCoy’s 5A medium
(Gibco, Grand Island, NY, USA) supplemented with 5% (vol/vol)
heat-inactivated fetal bovine serum and antibiotics at 37 °C in 5%
CO2. T84 was maintained in Dulbecco's modiﬁed Eagle's medium/F-12
1:1 mixture (Gibco) supplemented with 10% fetal bovine serum. HEK293T,
HT29, RKO and CaCo-2 cells were cultured in Dulbecco's modiﬁed Eagle's
medium with 10% fetal bovine serum. Human diploid ﬁbroblasts
(WI-38 and TIG-3) and SW480 cells were cultured in 10% fetal bovine
serum-containing minimum essential medium. For the analysis of cell
growth, appropriate numbers of HCT 116 or HEK293T cells were seeded in
tissue culture plates, and the number of growing cells was counted using
an automatic cell counter (Countess; Invitrogen, Carlsbad, CA, USA).
Cell numbers on the plates were also assessed using the CellTiter96
AQueous Cell Proliferation Assay (MTS) (Promega, Madison, WI, USA).
Apoptosis was evaluated by measuring cleaved caspase-9 and -3 levels by
western blotting, and TUNEL analysis using the DeadEnd Colorimetric
TUNEL system (Promega) according to the manufacturer’s protocol.
Percentages of TUNEL-positive cells in ﬁve different ﬁelds (400 nm2 each)
were calculated. The data were obtained in three independent
experiments. Cellular senescence was assessed by the expression of
SA-β-gal using an SA-β-gal Staining Kit (Cell Signaling Technology,
Danvers, MA, USA).
Northern blot analysis
Locked nucleic acid-modiﬁed oligonucleotide probes targeting TRA2β
transcripts (Gene Design, Osaka, Japan) were labeled with [32P]dCTP using
recombinant terminal deoxynucleotidyl transferase (Life Technologies,
Carlsbad, CA, USA). Oligonucleotide sequences using Northern blotting
were listed in Supplementary Table S1. Samples of total RNA were
separated in a 1% agarose gel containing 0.6 M formaldehyde and
transferred to a nylon membrane ﬁlter. After prehybridization, the
membrane was hybridized at 60 °C with the 32P-labeled probe overnight.
After washing, bound probes were analyzed by BAS 1500 Image Analyzer
(Fujiﬁlm, Tokyo, Japan).
Preparation of nuclear and cytosolic fractions
After HCT116 cells were incubated in cytosolic lysis buffer (10 mM Tris-HCl,
pH 7.4; 100 mM NaCl; 2.5 mM MgCl2; 40 μg/ml digitonin) for 10 min, lysates
were centrifuged at 2060 g for 8 min at 4 °C, and supernatants were
collected as cytosolic extracts. The remaining pellets were washed two
times with the cytosolic lysis buffer and lysed with RIPA buffer (10 mM
Tris-HCl, pH 7.4; 150 mM NaCl; 1 mM EDTA; 1 mM dithiothreitol; 0.1% sodium
dodecyl sulfate; 1% Nonidet P-40). After centrifugation at 21 000 g for
10 min at 4 °C, supernatants were collected as nuclear extracts. Cells lysed
with RIPA buffer were used as whole-cell extracts.
siRNAs
We used an siRNA (Hs_SFRS10_6 HP validated siRNA; Qiagen, Chatsworth,
CA, USA) to knock down exon 3-containing TRA2β1 and TRA2β4 mRNAs.
To silence selectively TRA2β4, exon 2-targeting siRNA was designed
(Supplementary Table S1). A negative control siRNA (AllStars Negative
Control siRNA) was obtained from Qiagen.
Quantitative real-time reverse transcription–PCR
Total RNAs were extracted from cells using TRIzol reagent
(Life Technologies). One microgram of isolated RNA was reverse-
transcribed using a PrimeScript RT Reagent Kit (Takara, Otsu, Japan).
TRA2β1, TRA2β4 and CDKNA1 mRNA levels were measured using SYBR
Green Master Mix and Applied Biosystems 7500 Real-time System (Applied
Biosystems, Foster City, CA, USA). The sequences of primer sets are
provided in Supplementary Table S1. TissueScan Tissue qPCR Arrays
(HCRT103) including cDNAs from paired normal and tumor tissues in 24
patients with adenocarcinomas of the colon were obtained from OriGene
Technologies (Rockville, MD, USA), and TRA2β4 levels in normal and tumor
tissues were determined by qPCR. TRA2β4 levels were measured by the
comparative ΔΔCt method using ACTBmRNA as a control and expressed as
values relative to the normal samples.
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Western blotting
Whole-cell lysates were prepared in a RIPA buffer (10 mM Tris-HCl, pH 7.4;
1% Nonidet P-40; 1 mM EDTA; 0.1% sodium dodecyl sulfate; 150 mM NaCl)
containing a protease and phosphatase inhibitor cocktail (Roche
Diagnostics Japan, Tokyo, Japan). Mouse monoclonal anti-α-tubulin
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Tra2β
(1:1000; Abcam, Cambridge, UK), anti-caspase-3 (1:1000; Cell Signaling
Technology, Danvers, MA, USA), anti-cleaved caspase-3 (1:1000;
Cell Signaling Technology), anti-PARP (1:1000; Cell Signaling Technology),
anti-cleaved PARP (1:1000; Cell Signaling Technology), anti-p21 (1:1000;
Santa Cruz Biotechnology), anti-p53 (1:1000; Santa Cruz Biotechnology),
anti-β-actin (1:1000; Abcam) or anti-Sp1 (1:1000, Santa Cruz Biotechnology)
antibody was used.
Promoter activity assay
The 5′ ﬂank of the human CDKNA1 gene was cloned into the pGL3-basic
luciferase reporter vector (Promega). In brief, the ﬁrst PCR was performed
using human genomic DNA as a template. The CDKNA1 proximal promoter
region was ampliﬁed using primer sets listed in Supplementary Table S1.
The ampliﬁed products were subcloned into the pGL3-basic vector using
HindIII and XhoI restriction sites. HCT116 cells (1.0 × 105) were cultured on
24-well plates, and then pGL3 luciferase constructs with various
site-directed mutation or deletion (100 ng) were co-transfected with
pRL-CMV vector (100 ng) using Jet-PEI (Polyplus Transfection, Illkirch,
France). Twenty-four hours after the transfection, cells were harvested
and the ﬁreﬂy and Renilla luciferase activities were measured using the
Dual-Luciferase Reporter Assay System (Promega).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed using the
Chromatin Immunoprecipitation Assay Kit (Millipore, Billerica, MA, USA).
Brieﬂy, HCT116 cells were ﬁxed with 1% formaldehyde in phosphate-
buffered saline for 10 min and then washed two times with ice-cold
phosphate-buffered saline. These cells were resuspended in sodium
dodecyl sulfate lysis buffer, incubated for 10 min on ice and then
sonicated. Immunoprecipitation was carried out overnight at 4 °C using
3 μg antibody against Sp1. Normal rabbit IgG was used to assess
nonspeciﬁc reactions. Immune complexes were collected with protein A
agarose/salmon sperm DNA. Crosslinking between proteins and DNA was
reversed according to the manufacturer’s protocol. Protein-bound DNA
was extracted with phenol/chloroform/isoamyl alcohol. The extracted DNA
was ampliﬁed by PCR (35 cycles; denaturing at 98 °C for 10 s, annealing at
55 °C for 30 s and extension at 72 °C for 1 min) using the following primers:
for the CDKNA1A sequence between − 560 and -226 bp, 5′-GGTG
TCTAGGTGCTCCAGGT-3′ and 5′-GCACTCTCCAGGAGGACACA-3′; for the
CDKNA1-B sequence between − 325 and +51 bp, 5′-CAGCGCACCAAC
GCAGGCG-3′ and 5′-CAGCTCCGGCTCCACAAGGA-3′. The nuclear chroma-
tin DNA from HCT116 cells (input) was used as a positive control for PCR.
Biotin pull-down assay
PCR fragments containing the T7 RNA polymerase promoter sequence
were used as templates for in vitro transcription. Biotinylated transcripts
were prepared by using a MEGAscript T7 Kit (Life Technologies) and biotin-
CTP (Perkin-Elmer Japan, Yokohama, Japan), and puriﬁed with ssDNA/RNA
Clean and ConcentratorTM (Zymo Research, Orange, CA, USA). Biotin
pull-down assays were carried out by incubating 40 μg of nuclear fractions
with 1 μg of biotinylated transcripts in TENT buffer (10 mM Tris-HCl (pH 8.0),
1 mM EDTA, 250 mM NaCl and 0.5% Triton X-100) for 1 h at room
temperature. Complexes were isolated with paramagnetic streptavidin-
conjugated Dynabeads (Life Technologies), and bound proteins in the
pull-down materials were analyzed by western blotting using an anti-Sp1
antibody.
RIP assay
HCT116 cells were lysed with 25 mM Tris-HCl buffer (pH 7.5) containing
150 mM NaCl, 1 mM EDTA, 1% (v/v) Nonidet P-40, 5% (v/v) glycerol and
100 U/ml RNase inhibitor (Promega). Whole-cell extracts (500 μg protein)
were incubated with protein A Sepharose beads precoated with 3 μg
anti-Sp1 antibody (Santa Cruz Biotechnology) or control rabbit IgG for 1 h
at 4 °C. After washing with NT2 buffer (50 mM Tris-HCl buffer, pH 7.4,
containing 150 mM NaCl2, 1 mM MgCl2 and 0.05% Nonidet P-40), beads
were incubated with 20 U of RNase-free DNase I (Life Technologies) in NT2
buffer for 15 min at 37 °C and further incubated in NT2 buffer
containing 0.1% sodium dodecyl sulfate and 0.5 mg/ml proteinase K
for 20 min at 55 °C. RNA in the IP materials was measured by qPCR.2
Fluorescent in situ hybridization
Cells were ﬁxed with 4% paraformaldehyde and permeabilized with 0.5%
Triton X for 5 min. RNA probes were prepared using Fluorescein
Isothiocyanate RNA Labeling Kit (Roche Diagnostic, Mannheim, Germany)
according to the manufacturer’s protocol. Then, cells were incubated for
16 h at 55 °C with 2 x SSC containing ﬂuorescein isothiocyanate-labeled
RNA probes. The cells were washed with 2 x SSC 55 °C for 30 min, the
nuclei were stained using TO-PRO-3 (Life Technologies) and coverslipped
with Vectashield (Life Technologies).
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